Healthquest Pharma, a wholly-owned subsidiary of Ascentage Pharma, established in 2012 , is a biotechnology company specialized in new drug development and related technology consulting services, and was recognized as a High-Tech Enterprise in 2022. All of the company s investigational assets are novel therapies of which Healthquest Pharma holds intellectual property rights. The orally active, third-generation TKI olverembatinib is the first and only China-approved third-generation BCR-ABL inhibitor targeting drug-resistant chronic myeloid leukemia (CML).